Mechanism
Indication(s)
Product Name
Discovery & Development
Preclinical
Phase 1
Phase 2
Phase 3

In order to obviate the use of chemotherapeutic agents for conditioning of patients undergoing BM/HSC transplantations, HemoGenyx developed a method of selective elimination of hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in patients using highly specific CDX antibodies[1]. CDX antibodies belong to a class of bi-specific antibodies that redirect patients’ own immune cells to eliminate HSC. In addition, CDX antibodies show promise in efficiently eliminating malignant cells belonging to a subset of leukemia. In sum, CDX antibodies have the potential to both eliminate malignant leukemic cells and increase the efficiency of conditioning while diminishing the side effects that accompany traditional methods of patient conditioning.